ChromaDex Appoints Frank Jaksch As Executive Chairman, Rob Fried as Chief Executive Officer and Kurt Gustafson as Lead Director
April 23, 2018 16:05 ET
|
ChromaDex Corporation
IRVINE, Calif., April 23, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, today announced a new...
TRU NIAGEN® to be featured at the American Academy of Anti-Aging Medicine Spring Congress
April 05, 2018 06:30 ET
|
ChromaDex Corporation
IRVINE, Calif., April 05, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it...
New Published Clinical Trial Confirms NIAGEN® Supplementation Raised Nicotinamide Adenine Dinucleotide (NAD) Levels and Potentially Improves Blood Pressure and Cardiovascular Health
March 29, 2018 07:30 ET
|
ChromaDex Corporation
IRVINE, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that...
ChromaDex Corporation Reports 2017 Financial Results
March 08, 2018 16:01 ET
|
ChromaDex Corporation
IRVINE, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to improving the way people age, announced today...
ChromaDex to Present at the 30th Annual ROTH Conference on March 12, 2018
March 06, 2018 06:30 ET
|
ChromaDex Corporation
IRVINE, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way...
ChromaDex Sets Fourth Quarter and Full Year 2017 Conference Call for Thursday, March 8, 2018 at 4:30 p.m. ET
March 02, 2018 06:30 ET
|
ChromaDex Corporation
IRVINE, Calif., March 02, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way...
Two Additional Collaborative Human Studies on NIAGEN® with the University of Cambridge and the University of Washington Now Registered on Clinical-trials.gov.
February 20, 2018 06:30 ET
|
ChromaDex Corporation
IRVINE, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today...
ChromaDex Chairman Stephen Allen Will Retire from Board of Directors
February 16, 2018 16:30 ET
|
ChromaDex Corporation
IRVINE, Calif., Feb. 16, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way...
ChromaDex Corporation Reports Preliminary 2017 Results
February 12, 2018 06:30 ET
|
ChromaDex Corporation
IRVINE, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way...
National Institutes of Health (NIH) Announces NIAGEN® Prevents Neurological Damage and Shows Improved Cognitive and Physical Function in a Mouse Model of Alzheimer’s Disease
February 08, 2018 06:30 ET
|
ChromaDex Corporation
IRVINE, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that the...